Heatwurx (PCSA) to Release Earnings on Wednesday

Heatwurx (NASDAQ:PCSA) is expected to announce its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

Heatwurx (NASDAQ:PCSA) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). On average, analysts expect Heatwurx to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Heatwurx Stock Performance

Shares of NASDAQ:PCSA opened at $0.30 on Wednesday. The firm has a 50 day simple moving average of $0.24 and a 200 day simple moving average of $0.25. The company has a market cap of $15.10 million, a PE ratio of -0.13 and a beta of 1.53. Heatwurx has a 52 week low of $0.15 and a 52 week high of $1.50.

Analyst Upgrades and Downgrades

PCSA has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heatwurx in a research report on Wednesday, October 8th. HC Wainwright decreased their target price on Heatwurx from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday, September 2nd. Finally, Zacks Research cut Heatwurx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 26th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Heatwurx currently has an average rating of “Hold” and a consensus price target of $1.00.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.